L3VLUP
ProSign in

ABBV · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABBVLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABBV
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterABBVLLY
Q3 202031 holders, $16.4bn33 holders, $14.1bn
Q4 202027 holders, $18.4bn29 holders, $17.3bn
Q1 202126 holders, $16.6bn24 holders, $23.0bn
Q2 202129 holders, $16.0bn24 holders, $27.8bn
Q3 202126 holders, $12.8bn31 holders, $29.9bn
Q4 202129 holders, $15.3bn31 holders, $34.7bn
Q1 202225 holders, $18.8bn24 holders, $35.3bn
Q2 202222 holders, $17.4bn33 holders, $42.7bn
Q3 202227 holders, $15.4bn31 holders, $43.4bn
Q4 202225 holders, $17.8bn31 holders, $46.6bn
Q1 202329 holders, $17.0bn33 holders, $44.3bn
Q2 202332 holders, $13.2bn37 holders, $59.6bn
Q3 202337 holders, $15.9bn44 holders, $67.6bn
Q4 202335 holders, $15.5bn45 holders, $73.6bn
Q1 202425 holders, $18.9bn41 holders, $95.3bn
Q2 202428 holders, $19.3bn43 holders, $110bn
Q3 202426 holders, $23.1bn45 holders, $107bn
Q4 202425 holders, $20.5bn46 holders, $93.9bn
Q1 202531 holders, $24.5bn42 holders, $98.4bn
Q2 202539 holders, $20.2bn43 holders, $93.2bn
Q3 202534 holders, $27.1bn39 holders, $86.7bn
Q4 202523 holders, $27.7bn41 holders, $123bn
Q1 202627 holders, $26.8bn39 holders, $106bn
Q2 202630 holders, $33.2bn44 holders, $132bn
ABBV

Abbvie Inc

Holders
25
Reported value
$20.5bn
Buyers
11
Sellers
12

Breadth -1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
46
Reported value
$93.9bn
Buyers
24
Sellers
23

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ABBV (2)

Arrowstreet Capital LP, Caxton Associates LLP

Only LLY (23)

Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Egerton Capital UK LLP, Jane Street Group LLC, Lone Pine Capital LLC, Millennium Management LLC, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, Tiger Global Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →